Age-associated DNA methylation changes have been widely reported across many 22 different tissue and cell types. Epigenetic 'clocks' that can predict chronological age with 23 a surprisingly high degree of accuracy appear to do so independently of tissue and cell- 24 type, suggesting that a component of epigenetic drift is cell-type independent. However, 25 the relative amount of age-associated DNAm changes that are specific to a cell or tissue 26 type versus the amount that occurs independently of cell or tissue type is unclear and a 27 matter of debate, with a recent study concluding that most epigenetic drift is tissue-28 specific. Here, we perform a novel comprehensive statistical analysis, including matched 29 multi cell-type and multi-tissue DNA methylation profiles from the same individuals and 30 adjusting for cell-type heterogeneity, demonstrating that a substantial amount of 31 epigenetic drift, possibly over 70%, is shared between significant numbers of different 32 tissue/cell types. We further show that ELOVL2 is not unique and that many other CpG 33 sites, some mapping to genes in the Wnt and glutamate receptor signaling pathways, are 34 altered with age across at least 10 different cell/tissue types. We propose that while most 35 2 age-associated DNAm changes are shared between cell-types that the putative functional 36 effect is likely to be tissue-specific. 37 38 Introduction 39 Age-associated DNA methylation (DNAm) changes have been reported for a long time 1-3 . One 40 of the first studies to indicate that age-associated DNAm changes, termed epigenetic drift, 41 could be largely tissue specific was a study by Christensen et al 4 . This first study however only 42 sampled a small percentage of the DNA methylome, was largely underpowered and did not 43 adjust for potentially confounding cell-type heterogeneity 5,6 . Building on an observation that 44 DNAm over specific Polycomb Repressor Complex-2 (PRC2) promoter loci correlates with 45 age across many different tissue-types 7 , it was demonstrated that age-associated DNAm 46 changes can be used to build remarkably accurate predictors of chronological age, termed 47 epigenetic clocks [8][9][10][11] , which also appear to work independently of tissue or cell-type 9 . 48 Interestingly, a recent study has suggested however that most age-associated DNAm changes 49 are tissue-specific 12 . Indeed, the study concluded that, with the exception of the ELOVL2 50 promoter, epigenetic drift is not shared between tissues. This is a surprising conclusion given 51 that several pan-tissue epigenetic clocks have been constructed 9,13,14 . It led us to investigate 52 the tissue and cell-type specific nature of epigenetic drift in more detail. In doing so, we have 53 identified a number of critical issues with the statistical analyses performed in 12 , which may 54 have led to premature conclusions. First, the study performs the primary analyses using very 55 stringent Bonferroni-corrected thresholds. While this controls for the Family-Wise-Error-Rate 56 (FWER), the use of a Bonferroni threshold is known to suffer from a very large False Negative 57 Rate (FNR), i.e. to a substantial reduction in power. This is particularly pertinent because their 58 analyses generally compare age-DMPs (aDMPs) between studies and tissues, which according 59 to our estimates were not adequately powered. Second, the authors do not report P-values of 60 overlap, only overlapping fractions, which does not allow the statistical significance of the 61 overlaps to be assessed. Assessing statistical significance is important because if aDMPs are 62 not preferentially shared between tissue-types, then the reported overlaps should not deviate 63 significantly from random. Third, the authors perform additional analyses using an arbitrary 64 threshold on the effect size, as an alternative to statistics and P-values to select aDMPs, to argue 65 that the "lack of overlap of aDMPs derived from different tissues" is not due to a lack of power.
substantially higher: at about n=600, sensitivity is already close to 1, and for 300 samples, 189 sensitivity is over 0.4 ( Fig.4B ). Thus, when comparing aDMPs between multiple cell or tissue-190 types it is even more critical to use FDR-based thresholds, since otherwise using based adjustment, the expected overlap of aDMPs derived from say 4 separate studies will be 192 zero, even if all aDMPs are common to all 4 cell/tissue-types. Our analysis suggests that many 193 hundreds if not thousands of samples would be needed to ensure that overlaps over 3 or more 194 studies would have the appropriate sensitivity to detect the majority of shared aDMPs ( Fig.4A-195 B). We verified that all these results are independent of whether an additional threshold on the 196 effect size is used to select aDMPs ( Fig.4C ). Indeed, using an additional and identical threshold 197 on the effect size to define aDMPs as used in 12 , i.e demanding at least a 2% change in DNAm Using only a threshold on effect size for feature selection suffers from strong selection bias 203 If we were to ignore statistical significance estimates (which depend on sample size) altogether, 204 and instead rank features by effect size using the above mentioned threshold (a 2% DNAm 205 change over 10 years) to declare aDMPs, we can see that sensitivities increase substantially, 206 exhibiting a much lower dependency on sample size (Fig.4D ). For instance, at n=100, the 207 sensitivity would be as high as 0.6 ( Fig.4D ). At first, this seems to support the argument by 208 Slieker et al that an observed lack of overlapping aDMPs defined via an effect size threshold 209 would imply that aDMPs are largely tissue-specific. However, this argument is incorrect, 210 primarily for two reasons. First, selecting aDMPs based on effect size still suffers from 211 selection bias, i.e. the fact that in the dataset where aDMPs are selected effect sizes will 212 naturally be higher than in independent studies. This selection bias arises in real data because 213 of numerous study-specific confounders which can significantly inflate or deflate effect sizes.
214
Indeed, our subsampling analysis shows that the sensitivity to detect aDMPs at a sample size 215 of 100 to be approximately 40% lower than at the full sample size (n=1199) (Fig.4D) , which 216 is a substantial reduction given that the subsample derives from the same dataset. While this 217 also demonstrates that using an effect size to rank and select aDMPs does not guarantee that 218 the ranking and selection is independent of sample size, as claimed in 12 , we stress that the 219 selection bias will be even more pronounced when comparing across independent studies. Thus, bias, and nothing to do with the nature of the different tissue being profiled.
223
A second major problem associated with using an effect size threshold to select and validate 224 aDMPs is related to confounding factors such as cell-type heterogeneity, which may artificially 225 deflate effect sizes in spite of associations with age remaining highly significant. To 226 demonstrate this, we posited that the fraction of aDMPs derived in the monocyte set that would normalized with BMIQ. 
